Saifullah H, Lucas C
Cancers (Basel). 2021; 13(16).
PMID: 34439327
PMC: 8392063.
DOI: 10.3390/cancers13164175.
Qin S, Jiang J, Lu Y, Nice E, Huang C, Zhang J
Signal Transduct Target Ther. 2020; 5(1):228.
PMID: 33028808
PMC: 7541492.
DOI: 10.1038/s41392-020-00313-5.
Moisoiu V, Teodorescu P, Parajdi L, Pasca S, Zdrenghea M, Dima D
Front Oncol. 2019; 9:863.
PMID: 31608223
PMC: 6768007.
DOI: 10.3389/fonc.2019.00863.
Zhang H, Li S
Stem Cells Transl Med. 2019; 8(8):768-774.
PMID: 31016860
PMC: 6646691.
DOI: 10.1002/sctm.18-0247.
Sweet K, Hazlehurst L, Sahakian E, Powers J, Nodzon L, Kayali F
Leuk Res. 2018; 74:89-96.
PMID: 30340199
PMC: 7787269.
DOI: 10.1016/j.leukres.2018.10.002.
Decreased expression of microRNA-214 contributes to imatinib mesylate resistance of chronic myeloid leukemia patients by upregulating ABCB1 gene expression.
Jin J, Yao J, Yue F, Jin Z, Li D, Wang S
Exp Ther Med. 2018; 16(3):1693-1700.
PMID: 30186389
PMC: 6122133.
DOI: 10.3892/etm.2018.6404.
Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy.
Woywod C, Gruber F, Engh R, Fla T
PLoS One. 2017; 12(7):e0179700.
PMID: 28678800
PMC: 5497988.
DOI: 10.1371/journal.pone.0179700.
Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/NF-κB inactivation.
Xu X, Zhang X, Zhang Y, Yang L, Liu Y, Huang S
Sci Rep. 2017; 7:39950.
PMID: 28150717
PMC: 5288730.
DOI: 10.1038/srep39950.
Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.
Schutz C, Inselmann S, Saussele S, Dietz C, Mu Ller M, Eigendorff E
Leukemia. 2017; 31(4):829-836.
PMID: 28074067
DOI: 10.1038/leu.2017.9.
The concept of treatment-free remission in chronic myeloid leukemia.
Saussele S, Richter J, Hochhaus A, Mahon F
Leukemia. 2016; 30(8):1638-47.
PMID: 27133824
PMC: 4980559.
DOI: 10.1038/leu.2016.115.
Salarin C inhibits the maintenance of chronic myeloid leukemia progenitor cells.
Del Poggetto E, Tanturli M, Ben-Califa N, Gozzini A, Tusa I, Cheloni G
Cell Cycle. 2015; 14(19):3146-54.
PMID: 26291130
PMC: 4825620.
DOI: 10.1080/15384101.2015.1078029.
Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (PDGFR-α, PDGFR-β, and c-kit).
Moawad E
J Gastrointest Cancer. 2015; 46(3):272-83.
PMID: 25985771
DOI: 10.1007/s12029-015-9721-4.
Interferon alpha 2 maintenance therapy may enable high rates of treatment discontinuation in chronic myeloid leukemia.
Burchert A, Saussele S, Eigendorff E, Muller M, Sohlbach K, Inselmann S
Leukemia. 2015; 29(6):1331-5.
PMID: 25712735
DOI: 10.1038/leu.2015.45.
Monitoring of response to therapy with imatinib mesylate in Chronic Myeloid Leukemia in chronic phase (CML-CP).
Nair V, Sharma A, Kotwal J, Bhikshapathy M, Mishra D, Das S
Med J Armed Forces India. 2014; 70(4):315-20.
PMID: 25382903
PMC: 4223192.
DOI: 10.1016/j.mjafi.2014.07.005.
Inhibition of STAT5: a therapeutic option in BCR-ABL1-driven leukemia.
Berger A, Sexl V, Valent P, Moriggl R
Oncotarget. 2014; 5(20):9564-76.
PMID: 25333255
PMC: 4259420.
DOI: 10.18632/oncotarget.2465.
Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia.
Sanford D, Kyle R, Lazo-Langner A, Xenocostas A, Chin-Yee I, Howson-Jan K
Curr Oncol. 2014; 21(2):e241-9.
PMID: 24764709
PMC: 3997457.
DOI: 10.3747/co.21.1736.
Cancer cell dormancy in novel mouse models for reversible pancreatic cancer: a lingering challenge in the development of targeted therapies.
Lin W, Rajbhandari N, Wagner K
Cancer Res. 2014; 74(8):2138-43.
PMID: 24670819
PMC: 3992817.
DOI: 10.1158/0008-5472.CAN-13-3437.
PTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemia.
Huang F, Zhang L, Wu D, Yuan X, Yu Y, Zhao X
PLoS One. 2014; 9(3):e88298.
PMID: 24603487
PMC: 3945754.
DOI: 10.1371/journal.pone.0088298.
Maintaining low BCR-ABL signaling output to restrict CML progression and enable persistence.
Burchert A
Curr Hematol Malig Rep. 2014; 9(1):9-16.
PMID: 24500518
PMC: 3930845.
DOI: 10.1007/s11899-013-0196-8.
Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.
Philips S, Hildenbrand Z, Oravecz-Wilson K, Foley S, Mgbemena V, Ross T
Oncogene. 2013; 33(46):5379-90.
PMID: 24240679
PMC: 4025985.
DOI: 10.1038/onc.2013.484.
